



PATENT  
ATTORNEY DOCKET NUMBER: 50125/045001

Certificate of Mailing: Date of Deposit: July 28, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Colleen Coyne  
Printed name of person mailing correspondence

Colleen Coyne  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michael Hallek et al.                      Art Unit: 1648  
Serial No.: 10/031,187                                      Examiner: H. Park  
Filed: January 18, 2002                                      Customer No.: 21559  
Title: SCLEROPROTEIN OF AN ADENO-ASSOCIATED VIRUS WITH  
MODIFIED CHROMATOGRAPHIC PROPERTIES, THE  
PRODUCTION THEREOF AND USE OF THE SAME

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office action on the merits, but before the mailing of a final Office action or a Notice of Allowance. A check for \$180.00 in payment of the late submission fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.


Respectfully submitted,

Date: 28 July 2005

  
\_\_\_\_\_  
Karen L. Elbing, Ph.D.  
Reg. No. 35,238

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

F:\50125\50125.045001 supplemetnal Information Disclosure Statement.doc



Sheet 1 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))				Attorney Docket No.		50125/045001	
				Serial No.		10/031,187	
				Applicant		Hallek et al.	
				Filing Date		January 18, 2002	
				Group		1648	
				IDS Filed		July 28, 2005	
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)	
	WO 99/67393	12/29/99	PCT				
	WO 97/38723	10/23/97	PCT				
	WO 96/00587	01/11/96	PCT				
	WO 95/23867	09/08/95	PCT				
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)							
	Aumailley et al., "Identification of the Arg-Gly-Asp Sequence in Laminin A Chain as a Latent Cell-Binding Site Being Exposed in Fragment P1," <i>FEBS</i> 262:82-86 (1990).						
	Bartlett et al., "Targeted Adeno-Associated Virus Vector Transduction of Nonpermissive Cells Mediated by a Bispecific F (ab') <sub>2</sub> Antibody," <i>Nature Biotechnology</i> 17:181-186 (1999).						
	Chapman et al., "Structure, Sequence, and Function Correlations Among Parvoviruses," <i>Virology</i> 194:491-508 (1993).						
	Chiorini et al., "High-Efficiency Transfer of the T Cell Co-Stimulatory Molecular B7-2 to Lymphoid Cells Using High-Titer Recombinant Adeno-Associated Virus Vectors," <i>Human Gene Therapy</i> 6:1531-1541 (1995).						
	Cosset et al., "Targeting Retrovirus Entry," <i>Gene Therapy</i> 3:946-956 (1996).						
	Douglas et al., "Targeted Gene Delivery by Tropism-Modified Adenoviral Vectors," <i>Nature Biotechnology</i> 14:1574-1578 (1996).						
	Girod et al., "Genetic Capsid Modifications Allow Efficient Re-Targeting of Adeno-Associated Virus Type 2," <i>Nature Medicine</i> 5:1052-1056 (1999).						
	Hermonat et al., "Genetics of Adeno-Associated Virus: Isolation and Preliminary Characterization of Adeno-Associated Virus Type 2 Mutants," <i>Journal of Virology</i> 51:329-339 (1984).						
	Luo et al., "Preliminary X-Ray Crystallographic Analysis of Canine Parovirus Crystals," <i>J. Mol. Biol.</i> 200:209-211 (1988).						
	Kotin, "Prospects for the Use of Adeno-Associated Virus as a Vector For Human Gene Therapy," <i>Human Gene Therapy</i> 5:793-801 (1994).						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))		Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50125/045001 10/031,187 Hallek et al. January 18, 2002 1648 July 28, 2005
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)			
	Krasnykh et al., "Generation of Recombinant Adenovirus Vectors With Modified Fibers for Altering Viral Tropism," <i>Journal of Virology</i> 70:6839-6846 (1996).		
	Muzyczka, "Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells," <i>Current Topics in Microbiology and Immunology</i> 158:97-129 (1992).		
	Nimako et al., "Human Papillomavirus-Specific Cytotoxic T Lymphocytes in Patients with Cervical Intraepithelial Neoplasia Grade III," <i>Cancer Research</i> 57:4855-4861 (1997).		
	Ohno et al., "Cell-Specific Targeting of Sindbis Virus Vectors Displaying IgG-Binding Domains of Protein A," <i>Nature Biotechnology</i> 15:763-767 (1997).		
	Ruffing et al., "Mutations in the Carboxy Terminus of Adeno-Associated Virus 2 Capsid Proteins Affect Viral Infectivity: Lack of an RGD Integrin-Binding Motif," <i>Journal of General Virology</i> 75:3385-3392 (1994).		
	Ruffing et al., "Assembly of Viruslike Particles by Recombinant Structural Proteins of Adeno-Associated Virus Type 2 in Insect Cells," <i>Journal of Virology</i> 66:6922-6930 (1992).		
	Rutledge et al., "Infectious Clones and Vectors Derived from Adeno-Associated Virus (AAV) Serotypes Other Than AAV Type 2," <i>Journal of Virology</i> 72:309-319 (1998).		
	Steinbach et al., "Assembly of Adeno-Associated Virus Type 2 Capsids in vitro," <i>Journal of General Virology</i> 78:1453-1462 (1997) (Abstract).		
	Stevenson et al., "Selective Targeting Human Cells by a Chimeric Adenovirus Vector Containing a Modified Fiber Protein," <i>Journal of Virology</i> 71:4782-4790 (1997).		
	Srivastava et al., "Nucleotide Sequence and Organization of the Adeno-Associated Virus 2 Genome," <i>Journal of Virology</i> 45:555-564 (1983).		
	Tarpey et al., "Human Cytotoxic T Lymphocytes Stimulated by Endogenously Processed Human Papillomavirus Type 11 E7 Recognize a Peptide Containing a HLA-A2 (A*0201) Motif," <i>Immunology</i> 81:222-227 (1994).		
	Tsao et al., "The Three-Dimensional Structure of Canine Parvovirus and Its Functional Implications," <i>Science</i> 251:1456-1464 (1991).		
	Valsesia-Wittmann et al., "Modifications in the Binding Domain of Avian Retrovirus Envelope Protein to Redirect the Host Range of Retroviral Vectors," <i>Journal of Virology</i> 68:4609-4619 (1994).		
	Wickham et al., "Increased In Vitro and In Vivo Gene Transfer by Adenovirus Vectors Containing Chimeric Fiber Proteins," <i>Journal of Virology</i> 71:8221-8229 (1997).		
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/045001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))		Serial No.	10/031,187
		Applicant	Hallek et al.
		Filing Date	January 18, 2002
		Group	1648
		IDS Filed	July 28, 2005
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)			
	Wickham et al., (1996), "Adenovirus Targeted to Heparan-containing Receptors Increases its Gene Delivery Efficiency to Multiple Cell Types," <i>Nat. Biotechnol.</i> , 14:1570-1573.		
	Wistuba et al., "Subcellular Compartmentalization of Adeno-Associated Virus Type 2 Assembly," <i>Journal of Virology</i> 71:1341-1352 (1997).		
	Wistuba et al., "Intermediates of Adeno-Associated Virus Type 2 Assembly: Identification of Soluble Complexes Containing Rep and Cap Proteins," <i>Journal of Virology</i> 69:5311-5319 (1995),		
	Wu et al., "The Canine Parvovirus Empty Capsid Structure," <i>J. Mol. Biol.</i> 233:231-244 (1993).		
	Yang et al., "Development of Novel Cell Surface CD34-Targeted Recombinant Adenoassociated Virus Vectors for Gene Therapy," <i>Human Gene Therapy</i> 9:1929-1937 (1998).		
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			